SANDOZ AND AVALON VENTURES TO PROVIDE BIOTECH START-UP FUNDING

SANDOZ AND AVALON VENTURES TO PROVIDE BIOTECH START-UP FUNDING for new firms, the companies announced Aug. 12. Sandoz and Avalon have formed Avalon Medical Partners, a 10-year partnership "targeted at creating leading-edge biopharmaceutical companies which will focus on the treatment of life-threatening diseases, chronic disorders and the diseases of aging," the two firms said. Sandoz will be the banker to the deal and Avalon will provide the active management. The agreement calls for the Swiss pharmaceutical firm to provide the predominant share of capital for the partnership, Sandoz said, although Avalon will also provide some capital. Avalon will provide the management team. The three general partners for Avalon Medical will be Kevin Kinsella, founding chairman of Athena Neurosciences, Synaptics, and Vertex, and present chairman of NeoRx; Larry Bock, formerly a Genentech research scientist and a founder of Athena Neuroscienes, GenPharm, and Vertex; and John Hendrick, an accountant with experience in financial posts at a number of firms. At Sandoz, the partnership will be a component of the company's "Innovascan" biotechnology investment program, announced earlier this year ("The Pink Sheet" Feb. 11, T&G-7). The partnership will allow Sandoz to invest in the earliest stages of promising new technology with the benefit of Avalon's experience in founding new biotechs, Sandoz said. Sandoz expects to spend $ 1 bil. investing in start-up companies over the next five years through Innovascan, including $ 150 mil. this year. The company would not assign a dollar value to the Avalon partnership. Avalon said that the partnership's total funding will be in the tens of millions of dollars. In addition to establishing start-ups, the partnership will "continue with Sandoz to nurture these and other innovative technology companies as appropriate," the two firms said. Although Avalon has previously focused exclusively on forming new companies, the venture firm said that the new partnership may also invest in established start-ups. However, Avalon said, such investment, while possible, is not probable, and would only be done at the behest of Sandoz. The partnership will follow the modus operandi of Avalon, the venture capital firm said. When a promising technology is selected, the partnership will form the company, initiate a private financing round, and have one of its members serve as chairman of the board. Sandoz will have little role in the actual management of companies founded, Avalon said. Sandoz will be in a position to step in early as a corporate partner. Avalon Ventures is a privately held La Jolla, Calif. firm that focuses on high tech startups. It has participated in the start-up of a number of healthcare companies, including Amer Particle Technologies, Ariad Pharmaceuticals, Athena Neurosciences, GenPharm, NeoRx, and Vertex.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

COVID-19 mRNA Vaccine Labels Now Quantify Myocarditis Risk, But ACIP Wants Other Changes

 
• By 

New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”